425: Strive to Acquire Semler Scientific in All-Stock Bitcoin Merger

Strive, Inc. will acquire Semler Scientific in an all-stock transaction, creating a combined entity with over 10,900 Bitcoin and a focus on preventative diagnostics.

Summary

• Strive, Inc. and Semler Scientific, Inc. entered into an Agreement and Plan of Merger on September 22, 2025, for an all-stock acquisition of Semler Scientific by Strive.
• The deal represents an approximately 210% premium, equivalent to $90.52 per share, based on the trading price of Semler Scientific common stock and Strive Class A common stock as of the market close on September 19, 2025.
• Each common share of Semler Scientific will be exchanged for 21.05 Class A common shares of Strive.
• Strive recently purchased 5,816 Bitcoin for its corporate treasury at an average price of $116,047 per Bitcoin, totaling $675,000,000, bringing Strive's total Bitcoin holdings to 5,886.
• The combined company is expected to own over 10,900 Bitcoin prior to any additional Bitcoin raised from future financings.
• Semler Scientific updated its previous guidance regarding new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling of QuantaFlo, now anticipated by the end of the second quarter of 2026 at the earliest.
• The combined company announces its post-merger intention to explore monetizing or distributing Semler Scientific's historically profitable diagnostics business at a future date, with a new management team and expanded mandate in preventative diagnostics.

Sentiment

Score: 8

Explanation: The merger offers a substantial premium to Semler Scientific shareholders and creates a significant Bitcoin-focused entity with a clear strategic vision. While there's a delay in FDA clearance for QuantaFlo, the overall strategic direction and value proposition for Semler shareholders are strong.

Positives

• Semler Scientific shareholders will receive a substantial premium of approximately 210%, or $90.52 per share, in the all-stock transaction.
• The merger creates a combined entity with significant Bitcoin holdings, projected to be over 10,900 Bitcoin, positioning it as a leading corporate Bitcoin holder.
• Strive's strategy aims to increase Bitcoin per share and outperform Bitcoin over the long run, utilizing a preferred equity-only leverage model to avoid debt maturity risks.
• The transaction allows Semler Scientific shareholders direct participation in one of the most innovative Bitcoin strategies in the public markets.
• The merger can drive shareholder value by expanding the medical diagnostics business into a robust preventative care and wellness platform focused on early detection of chronic disease.
• The boards of directors of both Strive and Semler Scientific unanimously approved the transaction.

Negatives

• New 510(k) clearance from the FDA for expanded labeling of QuantaFlo is delayed, now anticipated by the end of Q2 2026 at the earliest.
• The combined company intends to explore monetizing or distributing Semler Scientific's historically profitable diagnostics business at a future date, which could alter its core operations.
• The all-stock nature of the transaction means Semler Scientific shareholders will receive Strive shares, exposing them to Strive's share price fluctuations and Bitcoin-related risks.

Risks

• The proposed transaction may not close when expected or at all if the conditions to closing are not received or satisfied on a timely basis.
• Legal proceedings may be instituted against Strive, Semler Scientific, or the combined company.
• Anticipated benefits of the proposed transaction, including cost savings and strategic gains, may not be realized, particularly due to risks associated with Bitcoin treasury strategies and other digital assets.
• The integration of the two companies may be more difficult, time-consuming, or costly than expected.
• The proposed transaction may be more expensive or take longer to complete than anticipated due to unexpected factors or events.
• Management's attention may be diverted from ongoing business operations and opportunities during the merger process.
• Dilution may occur for Strive shareholders due to the issuance of additional shares of its Class A common stock in connection with the proposed transaction.
• Potential adverse reactions from customers or changes to business or employee relationships could result from the announcement or completion of the proposed transaction.
• Changes in Strive's or Semler Scientific's share price before closing could impact the value of the transaction.
• General economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement could affect future results.

Future Outlook

The combined company aims to become the fastest-growing corporate Bitcoin holder, operating with a preferred equity-only leverage model to avoid debt maturity risks. It intends to explore monetizing or distributing Semler Scientific's diagnostics business at a future date, with a new management team and an expanded mandate in preventative diagnostics. Semler Scientific anticipates new FDA 510(k) clearance for expanded QuantaFlo labeling by the end of Q2 2026 at the earliest.

Management Comments

• "We believe the combined company would become the fastest growing corporate Bitcoin holder, aiming to operate with a preferred equity only leverage model that avoids debt maturity risks associated with traditional leveraged Bitcoin strategies." Matt Cole, Chairman & CEO of Strive.
• "This merger cements Strive's position as a top Bitcoin treasury company, and we believe our alpha-seeking strategies and capital structure position us to outperform Bitcoin over the long run." Matt Cole, Chairman & CEO of Strive.
• "This transaction showcases how we can grow Bitcoin holdings and Bitcoin per share at an unmatched pace in the industry to drive equity value accretion." Matt Cole, Chairman & CEO of Strive.
• "We believe this merger creates significant value for our stockholders by delivering a substantial premium and direct participation in one of the most innovative Bitcoin strategies in the public markets." Eric Semler, Executive Chairman of Semler Scientific.
• "Just as importantly, this merger can drive shareholder value by expanding our medical diagnostics business into a robust preventative care and wellness platform focused on early detection of chronic disease." Eric Semler, Executive Chairman of Semler Scientific.
• "This dual-pronged strategy fuels both financial strength and mission-driven growth opportunities for our stakeholders." Eric Semler, Executive Chairman of Semler Scientific.

Industry Context

This merger signifies a growing trend of publicly traded companies integrating Bitcoin into their corporate treasury strategies, moving beyond traditional asset management. Strive's focus on increasing Bitcoin per share and its preferred equity leverage model represents an innovative approach in the digital asset space. The intention to expand Semler Scientific's preventative diagnostics business aligns with broader healthcare trends emphasizing early detection and wellness, while the potential monetization of the existing diagnostics business suggests a strategic pivot towards a more focused or streamlined healthcare offering within the combined entity.

Comparison to Industry Standards

• Strive's acquisition of Semler Scientific, creating a combined entity with over 10,900 Bitcoin, positions it among the largest corporate Bitcoin holders, comparable to companies like MicroStrategy, which pioneered the corporate Bitcoin treasury strategy.
• Strive's stated goal to "outperform Bitcoin over the long run" through "alpha-seeking strategies and capital structure" sets a high bar, differentiating it from passive Bitcoin holding strategies.
• The 210% premium offered to Semler Scientific shareholders is a significant valuation, indicating strong strategic interest and a potentially aggressive acquisition strategy by Strive compared to typical merger premiums.
• The combined entity's dual focus on Bitcoin treasury and preventative diagnostics, with a potential future divestiture of the existing diagnostics business, represents a unique hybrid model not commonly seen among either pure-play Bitcoin companies or traditional medical device firms.

Management Changes

Stakeholder Impact

• Shareholders (Semler Scientific): Will receive a significant premium (210% or $90.52 per share) and direct participation in Strive's Bitcoin strategy.
• Shareholders (Strive): Will experience dilution due to the issuance of new Class A common stock for the acquisition but will benefit from expanded Bitcoin holdings and strategic growth.
• Employees (Semler Scientific): The diagnostics business may see a new management team and potential monetization or distribution, which could impact employees.
• Customers (Semler Scientific): Potential changes to business relationships or product offerings if the diagnostics business is monetized or distributed.
• Regulatory Bodies (FDA): The delay in QuantaFlo's 510(k) clearance indicates ongoing regulatory engagement.

Next Steps

• Strive intends to file a Registration Statement on Form S-4 with the SEC to register Class A common stock to be issued in connection with the proposed transaction.
• The Registration Statement will include an Information Statement of Strive, a proxy statement of Semler Scientific, and a prospectus of Strive.
• A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval of the proposed transaction.
• Closing of the transaction is subject to the satisfaction of customary closing conditions.
• The combined company intends to explore monetizing or distributing Semler Scientific's diagnostics business at a future date.
• Semler Scientific anticipates new 510(k) clearance for expanded QuantaFlo labeling by the end of Q2 2026 at the earliest.

Key Dates

Recommendation

For Semler Scientific shareholders, the proposed all-stock merger with Strive offers a substantial premium of approximately 210% ($90.52 per share), representing a significant immediate value uplift. Furthermore, the transaction provides direct participation in a combined entity poised to be a leading corporate Bitcoin holder with an aggressive growth strategy in digital assets. While there is a delay in FDA clearance for QuantaFlo, the strategic pivot towards a larger, Bitcoin-centric enterprise, coupled with the premium, makes this a highly attractive proposition for Semler Scientific investors. For investors interested in the combined entity, this merger creates a scaled platform with a unique capital structure focused on outperforming Bitcoin, presenting a compelling long-term growth opportunity.

Keywords

Bitcoin, Merger, Acquisition, Semler Scientific, Strive, Medical Devices, Diagnostics, QuantaFlo, FDA, Preventative Care, Digital Assets, Treasury Strategy, All-Stock Transaction